Collectively, these studies capitalize on different optogenetic systems to control cellular activities for producing insulin in β cells or producing insulin and GLP‐1 in non‐β cells, which have demonstrated beneficial effects of DM therapy (Figure 1 and Table 2). This evidence concerns the gene GLP1R and diabetes mellitus.